Main Menu

Penalizing Generic Drugs with the CPI Rebate Will Reduce Competition and Likely Increase Drug Shortages

Richard Manning, Fred Selck
September 15, 2017
Read the article here

As part of the Bipartisan Budget Agreement of 2015, Congress extended the Consumer Price Index (CPI) rebate provisions to multisource generic drugs, aiming to control drug prices paid by the Medicaid program. Partner Richard Manning and Fred Selck provide evidence that these regulations may have precisely the opposite of their intended effect. The imposition of CPI penalties is likely to reduce the number of companies selling generics, which will increase the likelihood of shortages and may ultimately lead to higher generic drug prices over time.

Jump to Page

We use cookies to optimize the performance of this site and give you the best user experience. By clicking "Accept," you agree to our use of cookies.

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytical Cookies

Analytical cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.